Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

CFO Matt Abernethy projected INGREZZA sales for 2025 to range between $2.5 billion and $2.6 billion, reflecting $250 million growth at the midpoint. He noted increased competitive pressure and payer ...

Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...

A team of cardiac surgeons, led by Dr SS Lohchab, Senior Professor and Head, Department of Cardiac Surgery, Pt BD Sharma University of Health Sciences (UHS), saved the life of a patient undergoing ...

We recently published a list of 10 Stocks That Analysts Are Talking About. In this article, we are going to take a look at ...

Maria is best known for her work on steroid 21-hydroxylase deficiency, the most common form of congenital adrenal hyperplasia (CAH). Most of her fellows and trainees in the late 1970s and early 1980s ...

From January 2009 to January 2011, PVP surgery was conducted on 120 patients with a 120 watt green laser. Table 1 shows the basic patient data. Of all the patients, 30% took an oral anti-coagulant ...

[16] These results suggest that ejaculatory disorder caused by silodosin associated with very large improvements in patients with benign prostatic hyperplasia. On the other hand, 76% of the ...

Patients are dying in corridors and pregnant women are miscarrying in side rooms as overwhelmed hospitals struggle to cope, nurses say. The Royal College of Nursing (RCN) said evidence provided by ...